688117.SHG Cheng Du Sheng Nuo Biotec Co. Ltd. A
- Market cap
- CNY 3.29B
- P/E
- 15.5x
- P/B
- 2.64x
- ROE
- 19.2%
- Dividend yield
- 1.09%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688117.SHG undervalued?
Graham number688117.SHG trades 34.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cheng Du Sheng Nuo Biotec Co. Ltd. A fundamental analysis
No fundamental analysis for Cheng Du Sheng Nuo Biotec Co. Ltd. A yet.
Cheng Du Sheng Nuo Biotec Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cheng Du Sheng Nuo Biotec Co. Ltd. A
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. It provides semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, d…
Full company profileCheng Du Sheng Nuo Biotec Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cheng Du Sheng Nuo Biotec Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 194M | 278M | 327M | 379M | 387M | 396M | 435M | 456M | 741M | 988M |
| Gross Profit | 126M | 191M | 255M | 294M | 276M | 253M | 272M | 254M | 741M | 543M |
| Operating Income | 39.2M | 34.4M | 57.6M | 69.8M | 75.8M | 72.8M | 81.1M | 62.1M | 201M | 302M |
| EBITDA | 52.2M | 47.8M | 70.2M | 86.1M | 88.6M | 99.6M | 117M | 107M | 222M | 283M |
| Net Income | 33.9M | 29.9M | 48.1M | 60.0M | 61.3M | 64.5M | 70.3M | 50.0M | 166M | 227M |
| EPS | 0.30 | 0.26 | 0.41 | 0.51 | 0.43 | 0.41 | 0.44 | 0.31 | 1.05 | 1.03 |
| Balance Sheet | ||||||||||
| Total Assets | 348M | 478M | 519M | 593M | 957M | 1.11B | 1.32B | 1.65B | 1.93B | 2.17B |
| Total Liabilities | 106M | 151M | 142M | 155M | 171M | 281M | 436M | 730M | 877M | 989M |
| Shareholders' Equity | 242M | 327M | 376M | 438M | 785M | 827M | 880M | 918M | 1.06B | 1.18B |
| Cash & Short-term Investments | 36.5M | 121M | 104M | 130M | 412M | 372M | 269M | 239M | 281M | 178M |
| Total Debt | 15.0M | 15.4M | 457K | - | 32.9M | 103M | 227M | 382M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 58.2M | 66.2M | 30.9M | 80.8M | 52.4M | 95.6M | 86.5M | 25.3M | 178M | - |
| Capital Expenditure | 35.1M | 31.4M | 30.8M | 52.0M | 64.2M | 136M | 278M | 247M | 146M | 150M |
| Free Cash Flow | 23.1M | 34.9M | 75.4K | 28.9M | -11.8M | -40.2M | -193M | -222M | 32.7M | -53.6M |
| Ratios | ||||||||||
| ROE | 14.0% | 9.1% | 12.8% | 13.7% | 7.8% | 7.8% | 8.0% | 5.4% | 15.7% | 19.2% |
| ROA | 9.7% | 6.2% | 9.3% | 10.1% | 6.4% | 5.8% | 5.3% | 3.0% | 8.6% | 10.5% |
| Net Profit Margin | 17.4% | 10.7% | 14.7% | 15.8% | 15.8% | 16.3% | 16.2% | 11.0% | 22.4% | 23.0% |
| Debt to Equity | 0.06x | 0.05x | 0.00x | - | 0.04x | 0.12x | 0.26x | 0.42x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cheng Du Sheng Nuo Biotec Co. Ltd. A dividends
- Dividend yield
- 1.09%
- Forward dividend
- 0.34 CNY
- Payout ratio
- 21.7%
- Ex-dividend date
- Jun 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 36.0M | 0.23 | 21.7% |
| 2024 | CNY 34.2M | 0.21 | 68.3% |
| 2023 | CNY 29.2M | 0.18 | 41.5% |
| 2022 | CNY 24.0M | 0.15 | 37.2% |
| 2021 | CNY 25.0K | 0.00 | 0.0% |
| 2020 | - | - | - |
| 2019 | CNY 401K | 0.00 | 0.8% |
| 2018 | 416K | 0.00 | 1.4% |
| 2017 | 29.0M | 0.26 | 85.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 5, 2026.
Who owns Cheng Du Sheng Nuo Biotec Co. Ltd. A
- Insiders 46.74%
- Institutions 5.48%
- Public & others 47.79%
- Shares outstanding 220M
- Free float 137M
Cheng Du Sheng Nuo Biotec Co. Ltd. A company profile
- Company name
- Cheng Du Sheng Nuo Biotec Co. Ltd. A
- Ticker
- 688117.SHG
- ISIN
- CNE1000051M8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,605
- Fiscal year end
- December
- Address
- No. 98, Da'an Road, Dayi County, Chengdu, China, 611330
- Phone
- 86 28 8820 3630
- Website
- snbiopharm.com
About Cheng Du Sheng Nuo Biotec Co. Ltd. A
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. It provides semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. ChengDu ShengNuo Biotec Co.,Ltd. was founded in 2001 and is based in Chengdu, China.
Cheng Du Sheng Nuo Biotec Co. Ltd. A management
8- Mr. Yongjun WenChairman & GM · born 1965
- Mr. Xiaohai YuVice Chairman & Deputy GM · born 1988
- Mr. Li WuCFO, Deputy GM & Director · born 1974
- Ms. Xiaoli WangDirector and Deputy General Manager · born 1970
- Mr. Changliang LuDeputy General Manager · born 1970
- Mr. Zhonggang MaDeputy General Manager · born 1981
- Yang ShiAccounting Supervisor
- Ms. Dewen GuoKey Technical Personnel · born 1974